In a new review of eight studies published in the British Journal of Nutrition, researchers say that a 250-mg dose of omega-3 fatty acids can help lower the risk of fatal coronary heart disease.
In a new review of eight studies published in the British Journal of Nutrition, researchers say that a 250-mg dose of omega-3 fatty acids can help lower the risk of fatal coronary heart disease.
The review identified eight studies (seven cohort studies and one nested case-control study) that met inclusion criteria. It found that daily consumption of 250 mg of omega-3 fatty acids was associated with a significant 35% reduction in the risk of sudden cardiac death and a near-significant 16% reduction in the risk of total fatal coronary events. However, the risk of non-fatal myocardial infarction was not significantly reduced.
The researchers noted that in several meta-analyses of U.S. studies, risk of cardiovascular disease-related death was dose dependently reduced by omega-3 intake, and that further risk reductions were attributed to omega-3 intake exceeding 250 mg/day.
“Thus, the intake of 250 mg n-3 LCFA per d may, indeed, be a minimum target to be achieved by the general population for the promotion of cardiovascular health,” the researchers stated.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.